Do analysts recommend ALLR or CDIO?

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 655.34%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer NXTC or CDIO?

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 211.94%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts clearly believe NextCure is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NXTC or CDIO more profitable?

NextCure has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% Cardio Diagnostics -43,133.33% -82.28% -76.03%

Do analysts recommend CDIO or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend CDIO or NEUP?

Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 448.30%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer CDIO or NEUP?

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 1.15 beat Neuphoria Therapeutics' score of 0.96 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CDIO or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CDIO or QNTM?

In the previous week, Quantum Biopharma had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Quantum Biopharma and 3 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.15 beat Quantum Biopharma's score of 0.47 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardio Diagnostics (CDIO) Competitors

$1.88 -0.05 (-2.59%)

As of 10:16 AM Eastern

Compare

CDIO vs. ALLR, NXTC, ALVR, NEUP, and QNTM

Should you buy Cardio Diagnostics stock or one of its competitors? Cardio Diagnostics's main competitors and comparable companies include Allarity Therapeutics (ALLR), NextCure (NXTC), AlloVir (ALVR), Neuphoria Therapeutics (NEUP), and Quantum Biopharma (QNTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardio Diagnostics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Allarity Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 655.34%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Allarity Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cardio Diagnostics had 2 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Cardio Diagnostics and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat Cardio Diagnostics' score of 1.15 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Very Positive
Cardio Diagnostics	Positive

Cardio Diagnostics has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	67.47	-$11.23M	-$0.78	N/A
Cardio Diagnostics	$10K	556.48	-$6.50M	-$2.92	N/A

Summary

Allarity Therapeutics beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to NextCure?

NextCure (NASDAQ:NXTC) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

NextCure has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Cardio Diagnostics	$10K	556.48	-$6.50M	-$2.92	N/A

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 211.94%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts clearly believe NextCure is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.7% of NextCure shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NextCure has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

In the previous week, Cardio Diagnostics had 2 more articles in the media than NextCure. MarketBeat recorded 3 mentions for Cardio Diagnostics and 1 mentions for NextCure. NextCure's average media sentiment score of 1.87 beat Cardio Diagnostics' score of 1.15 indicating that NextCure is being referred to more favorably in the media.

Company	Overall Sentiment
NextCure	Very Positive
Cardio Diagnostics	Positive

Summary

Cardio Diagnostics beats NextCure on 8 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to AlloVir?

Cardio Diagnostics (NASDAQ:CDIO) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

AlloVir has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. AlloVir's return on equity of -71.03% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
AlloVir	N/A	-71.03%	-61.27%

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cardio Diagnostics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Cardio Diagnostics and 0 mentions for AlloVir. Cardio Diagnostics' average media sentiment score of 1.15 beat AlloVir's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardio Diagnostics has higher revenue and earnings than AlloVir. Cardio Diagnostics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	556.48	-$6.50M	-$2.92	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Cardio Diagnostics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Summary

Cardio Diagnostics beats AlloVir on 7 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Neuphoria Therapeutics has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	556.48	-$6.50M	-$2.92	N/A
Neuphoria Therapeutics	$15.65M	1.32	-$370K	-$11.06	N/A

Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 448.30%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 1.15 beat Neuphoria Therapeutics' score of 0.96 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuphoria Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Neuphoria Therapeutics' return on equity of -76.93% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Cardio Diagnostics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Summary

Neuphoria Therapeutics beats Cardio Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Quantum Biopharma?

Cardio Diagnostics (NASDAQ:CDIO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardio Diagnostics has higher revenue and earnings than Quantum Biopharma. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	556.48	-$6.50M	-$2.92	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

In the previous week, Quantum Biopharma had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Quantum Biopharma and 3 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.15 beat Quantum Biopharma's score of 0.47 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

Cardio Diagnostics beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.57M	$4.00B	$7.23B	$12.87B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-0.64	11.49	272.48	24.29
Price / Sales	556.48	1,304.68	608.54	79.97
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	0.75	16.72	13.12	6.25
Net Income	-$6.50M	-$22.76M	$3.47B	$348.11M
7 Day Performance	-14.93%	3.34%	2.05%	1.47%
1 Month Performance	16.05%	11.53%	8.25%	4.70%
1 Year Performance	-49.73%	58.10%	26.26%	17.01%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.8487 of 5 stars	$1.88 -2.6%	N/A	-47.4%	$5.57M	$10K	N/A	1	News Coverage Positive News
ALLR Allarity Therapeutics	2.8347 of 5 stars	$1.37 +2.7%	$10.25 +650.4%	-6.3%	$21.73M	$320K	N/A	10	Positive News Gap Up
NXTC NextCure	3.7597 of 5 stars	$6.00 +1.4%	$19.00 +216.9%	+11.7%	$21.64M	N/A	N/A	90	Positive News Gap Up
ALVR AlloVir	N/A	$4.20 +2.4%	N/A	+67.3%	$21.18M	N/A	N/A	110
NEUP Neuphoria Therapeutics	3.0765 of 5 stars	$3.89 +0.8%	$21.00 +439.7%	-53.3%	$21.01M	$15.65M	N/A	N/A	News Coverage Upcoming Earnings Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. ALLR, NXTC, ALVR, NEUP, and QNTM

How does Cardio Diagnostics compare to Allarity Therapeutics?

Summary

How does Cardio Diagnostics compare to NextCure?

Summary

How does Cardio Diagnostics compare to AlloVir?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Summary

How does Cardio Diagnostics compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. ALLR, NXTC, ALVR, NEUP, and QNTM

How does Cardio Diagnostics compare to Allarity Therapeutics?

Which has more risk and volatility, ALLR or CDIO?

Do analysts recommend ALLR or CDIO?

Is ALLR or CDIO more profitable?

Do institutionals & insiders believe in ALLR or CDIO?

Does the media prefer ALLR or CDIO?

Which has preferable earnings & valuation, ALLR or CDIO?

Summary

How does Cardio Diagnostics compare to NextCure?

Which has more volatility and risk, NXTC or CDIO?

Which has better earnings and valuation, NXTC or CDIO?

Do analysts prefer NXTC or CDIO?

Do institutionals and insiders have more ownership in NXTC or CDIO?

Is NXTC or CDIO more profitable?

Does the media refer more to NXTC or CDIO?

Summary

How does Cardio Diagnostics compare to AlloVir?

Is CDIO or ALVR more profitable?

Do institutionals & insiders believe in CDIO or ALVR?

Does the media prefer CDIO or ALVR?

Do analysts recommend CDIO or ALVR?

Which has stronger earnings & valuation, CDIO or ALVR?

Which has more volatility and risk, CDIO or ALVR?

Summary

How does Cardio Diagnostics compare to Neuphoria Therapeutics?

Which has stronger valuation & earnings, CDIO or NEUP?

Do analysts recommend CDIO or NEUP?

Do institutionals & insiders believe in CDIO or NEUP?

Does the media prefer CDIO or NEUP?

Is CDIO or NEUP more profitable?

Which has more risk and volatility, CDIO or NEUP?

Summary

How does Cardio Diagnostics compare to Quantum Biopharma?

Do analysts rate CDIO or QNTM?

Which has higher valuation and earnings, CDIO or QNTM?

Which has more volatility and risk, CDIO or QNTM?

Does the media prefer CDIO or QNTM?

Do insiders & institutionals have more ownership in CDIO or QNTM?

Is CDIO or QNTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools